PMGC Holdings Inc. (ELAB) - 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. PMGC Holdings Inc. is a diversified holding company operating through three primary segments: Corporate/Treasury/Biosciences, IT Packaging Solutions, and Precision Engineering/Machining. The company is classified as a smaller reporting company and an emerging growth company. During the period, the company significantly expanded its manufacturing footprint through the acquisitions of SVM Machining, Inc. (February 2026) and A&B Aerospace, Inc. (May 2026).
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Value |
|---|---|
| Revenue | $1,988,604 |
| Cost of Goods Sold | $1,372,439 |
| Gross Profit | $616,165 (31.0% Margin) |
| Operating Expenses | $7,776,548 |
| Net Loss (Continuing Ops) | $(7,945,732) |
| Total Net Loss | $(7,908,641) |
| Cash and Equivalents | $18,141,758 |
| Working Capital | $5,504,403 |
| Convertible Debt (Current) | $9,075,483 |
| Derivative Liabilities | $743,942 |
Material Changes vs. Prior Period
- Revenue Generation: Revenue increased from $0 in the prior year period to $1.99 million, driven entirely by newly acquired manufacturing subsidiaries (Pacific Sun, AGA, SVM, and A&B). The prior period had no continuing revenue operations following the disposal of the skincare business.
- Operating Expenses: Total operating expenses surged to $7.78 million from $2.22 million. Key drivers included:
- Consulting Fees: Increased to $2.44 million (from $0.75 million), primarily due to $2.08 million in contractual bonuses to key management.
- Office & Admin: Increased to $2.99 million (from $0.53 million) due to integration costs, rent for new facilities, and share-based compensation ($182,761).
- Professional Fees: Increased to $1.14 million (from $0.55 million) due to legal and audit fees related to acquisitions and financing.
- Other Income/Expense: Shifted from a net income of $54,941 to a net expense of $785,349. This was driven by $1.06 million in interest expense and $0.62 million in finance costs related to convertible debt, partially offset by a $0.70 million gain on the change in fair value of derivative liabilities.
- Balance Sheet: Total assets grew from $12.9 million to $36.6 million, largely due to cash inflows from financing and the acquisition of assets. Total liabilities increased from $5.0 million to $19.8 million, primarily due to convertible debt and lease liabilities.
Guidance, Outlook, and Risks
- Going Concern: The filing explicitly states that the company's substantial accumulated deficit ($28.9 million) and recurring net losses raise substantial doubt about its ability to continue as a going concern. Management's plan to alleviate this doubt relies on raising additional debt/equity financing and acquiring cash-flow-generating assets.
- Financing Activities: The company raised significant capital through two Equity Line of Credit (ELOC) agreements (totaling up to $60 million). During the period, it received net proceeds of approximately $22.9 million from pre-paid purchases and issued shares to settle portions of this debt.
- Strategic Outlook: Management intends to focus on advancing clinical development for NorthStrive Biosciences (specifically the EL-22 asset), pursuing additional acquisitions of B2B companies with positive EBITDA, and potentially creating new SPACs.
- Risks: Key risks include the ability to secure future financing, integration risks of recent acquisitions, volatility in derivative liabilities, and the uncertainty of the NorthStrive Acquisition Corp I IPO (filed July 2026).
Investor Verification Checklist
- Debt Settlement Terms: Verify the conversion rates and floor prices for the $9.1 million in current convertible debt under the ELOC agreements, as these significantly impact potential dilution.
- Related Party Transactions: Review the $2.88 million in total remuneration to key management personnel, including $2.08 million in bonuses and significant consulting fees to entities controlled by the CEO and Chairman.
- Acquisition Integration: Assess the revenue contribution and gross margins of the newly acquired machining subsidiaries (SVM and A&B) to determine if they are meeting the projected EBITDA targets.
- Derivative Liability Volatility: Monitor the fair value of derivative liabilities ($743,942), as fluctuations directly impact net income/loss.
- Cash Burn Rate: Evaluate the sustainability of the $18.1 million cash balance against the $4.97 million operating cash burn for the six-month period.